AZ: We’ll pick our emerging-markets fights
Picky, picky, picky. That’s what AstraZeneca says it will be as it pushes for double-digit growth in emerging markets, Reuters reports. Rather than leaping into branded generics indiscriminately, the company plans to focus on about 100 medicines in 30 markets where it can get the sort of prices that make the selling worthwhile. “We will be very selective in branded generics,” AstraZeneca’s Tony Zook told reporters before an investor briefing today (as quoted by Reuters ). The company just made its first branded generics deal in India , with a supply pact with Torrent Pharmaceuticals.
